May 6, 2024 07:20 AM EDT
R&D

Gly­coMimet­ic­s' AML drug flunks Phase 3 tri­al, quash­ing fil­ing plans as stock sinks

Katherine Lewin

News Reporter

Gly­coMimet­ics’ stock $GLYC tanked over 60% in pre­mar­ket trad­ing Mon­day morn­ing af­ter the biotech an­nounced a Phase 3 tri­al fail­ure for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Key GOP sen­a­tor is ‘strug­gling’ with Kennedy nom­i­na­tion over vac­cine an­swers

Black­stone se­cures $1.6B so far for new life sci­ences fund tar­get­ed at $5B+

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

Take­da scraps pro­grams as it rais­es full-year guid­ance 

FDA ap­proves Ax­some's acute mi­graine treat­ment af­ter 2022 re­jec­tion

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times